ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
ENANTA PHARMACEUTICALS INC
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.41+0.31 (+2.79%)
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
ENANTA PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty [Member] | $65.32M | $67.64M | $78.20M | $86.16M | $97.07M | $122.47M | $205.20M | $191.63M | $37.81M | $57.69M | 100.0% | -3.4% |
| License [Member] | $0 | $0 | $1.00M | $0 | $0 | – | – | – | – | – | 0.0% | – |
| Milestone [Member] | – | – | – | – | – | – | – | $15.00M | $65.00M | $30.00M | – | – |
| Revenue from Grants [Member] | – | – | – | – | – | – | – | – | – | $576.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Enanta Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.